“Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis”, J of Skin, vol. 8, no. 6, p. s441, Nov. 2024, doi: 10.25251/skin.8.supp.441.